Palatin Technologies, Inc. Common Stock - Asset Resilience Ratio
Palatin Technologies, Inc. Common Stock (PTN) has an Asset Resilience Ratio of 80.75% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Palatin Technologies, Inc. Common Stock strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Palatin Technologies, Inc. Common Stock's Asset Resilience Ratio has changed over time. See PTN equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Palatin Technologies, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PTN market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $14.48 Million | 80.75% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $14.48 Million | 80.75% |
Asset Resilience Insights
- Very High Liquidity: Palatin Technologies, Inc. Common Stock maintains exceptional liquid asset reserves at 80.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Palatin Technologies, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Palatin Technologies, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Palatin Technologies, Inc. Common Stock (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Palatin Technologies, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 78.49% | $2.56 Million | $3.27 Million | -10.20pp |
| 2024-06-30 | 88.69% | $9.53 Million | $10.74 Million | +27.47pp |
| 2023-06-30 | 61.22% | $10.98 Million | $17.94 Million | -21.78pp |
| 2022-06-30 | 83.00% | $29.94 Million | $36.07 Million | -6.31pp |
| 2021-06-30 | 89.31% | $60.10 Million | $67.30 Million | -8.10pp |
| 2020-06-30 | 97.41% | $82.85 Million | $85.05 Million | +55.87pp |
| 2019-06-30 | 41.54% | $43.51 Million | $104.74 Million | -56.49pp |
| 2018-06-30 | 98.03% | $38.25 Million | $39.02 Million | +26.86pp |
| 2017-06-30 | 71.17% | $40.45 Million | $56.83 Million | +58.68pp |
| 2016-06-30 | 12.49% | $1.38 Million | $11.05 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $29.47 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $12.56 Million | -- |
| 2013-06-30 | 20.94% | $5.25 Million | $25.07 Million | +14.43pp |
| 2012-06-30 | 6.50% | $350.00K | $5.38 Million | -21.44pp |
| 2010-06-30 | 27.95% | $3.46 Million | $12.39 Million | +1.89pp |
| 2009-06-30 | 26.06% | $3.44 Million | $13.20 Million | +8.53pp |
| 2008-06-30 | 17.53% | $3.35 Million | $19.12 Million | +12.10pp |
| 2007-06-30 | 5.43% | $2.32 Million | $42.78 Million | -0.39pp |
| 2006-06-30 | 5.82% | $2.33 Million | $40.05 Million | -0.96pp |
| 2005-06-30 | 6.78% | $2.39 Million | $35.17 Million | -3.33pp |
| 2004-06-30 | 10.11% | $2.47 Million | $24.38 Million | -7.88pp |
| 2003-06-30 | 17.99% | $4.09 Million | $22.72 Million | -6.27pp |
| 2000-06-30 | 24.26% | $2.16 Million | $8.89 Million | +13.62pp |
| 1999-06-30 | 10.64% | $500.00K | $4.70 Million | -- |
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more